Methylene Blue in Septic Shock: A Systematic Review and Meta-Analysis (2024)

Peer-Reviewed Study · Fernando SM, Tran A, Soliman K, Flynn B, Oommen T, Wenzhe L, Adhikari NKJ, Kanji S, Seely AJE, Fox-Robichaud AE, Wax RS, Cook DJ · June 21, 2024

Fernando SM et al., 2024-06-21: Systematic review and meta-analysis pooling six randomised trials (302 patients) of methylene blue in septic shock, finding possible reductions in short-term mortality and vasopressor duration on low-certainty evidence. It aggregates the doses used across the trial literature.

We included six RCTs (302 patients).

Fernando SM et al., 2024-06-21: Systematic review and meta-analysis pooling six randomised trials (302 patients) of methylene blue in septic shock, finding possible reductions in short-term mortality and vasopressor duration on low-certainty evidence. It aggregates the doses used across the trial literature. Study type: systematic review and meta-analysis of RCTs. N=302 patients across 6 RCTs. Countries: trials from Greece, Turkey, Mexico and others (see paper). Doses: as reported by the included trials (bolus plus infusion regimens from 1 to 5.75 mg/kg). Route: intravenous. Comparator: placebo or usual care without MB. Result: short-term mortality RR 0.66 (0.47-0.94), low certainty; vasopressor duration -31.1 h; no difference in adverse events. COI: 'Dr. Seely holds patents related to multiorgan variability analysis and has shares in Therapeutic Monitoring Systems. Dr. Cook is supported by a Canada Research Chair…' Funder: not stated in record. Note: the review's certainty ratings are low to very low; it does not establish benefit. Study type: review.